ArriVent Biopharma announces $75M common stock, warrants offering

ArriVent BioPharma (AVBP) announced that it intends to offer and sell, subject to market and other conditions, $75M of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities are being offered by ArriVent. ArriVent intends to use the net proceeds from the proposed offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for working capital and other general corporate purposes. Goldman Sachs & Co., Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.